AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice.
Adeno-associated viral vectors
Bioinformatics
CRISPR-Cas13d
Enterovirus
Prophylactic
Therapeutic
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
15
02
2023
revised:
13
06
2023
accepted:
13
06
2023
medline:
17
7
2023
pubmed:
1
7
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
RNA viruses account for many human diseases and pandemic events but are often not targetable by traditional therapeutics modalities. Here, we demonstrate that adeno-associated virus (AAV) -delivered CRISPR-Cas13 directly targets and eliminates the positive-strand EV-A71 RNA virus in cells and infected mice. We developed a Cas13gRNAtor bioinformatics pipeline to design CRISPR guide RNAs (gRNAs) that cleave conserved viral sequences across the virus phylogeny and developed an AAV-CRISPR-Cas13 therapeutics using in vitro viral plaque assay and in vivo EV-A71 lethally-infected mouse model. We show that treatment with a pool of AAV-CRISPR-Cas13-gRNAs designed using the bioinformatics pipeline effectively blocks viral replication and reduces viral titers in cells by >99.99%. We further demonstrate that AAV-CRISPR-Cas13-gRNAs prophylactically and therapeutically inhibited viral replication in infected mouse tissues and prevented death in a lethally challenged EV-A71-infected mouse model. Our results show that the bioinformatics pipeline designs efficient CRISPR-Cas13 gRNAs for direct viral RNA targeting to reduce viral loads. Additionally, this new antiviral AAV-CRISPR-Cas13 modality represents an effective direct-acting prophylactic and therapeutic agent against lethal RNA viral infections. Agency for Science, Technology and Research (A∗STAR) Assured Research Budget, A∗STAR Central Research Fund UIBR SC18/21-1089UI, A∗STAR Industrial Alignment Fund Pre-Positioning (IAF-PP) grant H17/01/a0/012, MOE Tier 2 2017 (MOE2017-T2-1-078; MOE-T2EP30221-0005), and NUHSRO/2020/050/RO5+5/NUHS-COVID/4.
Sections du résumé
BACKGROUND
BACKGROUND
RNA viruses account for many human diseases and pandemic events but are often not targetable by traditional therapeutics modalities. Here, we demonstrate that adeno-associated virus (AAV) -delivered CRISPR-Cas13 directly targets and eliminates the positive-strand EV-A71 RNA virus in cells and infected mice.
METHODS
METHODS
We developed a Cas13gRNAtor bioinformatics pipeline to design CRISPR guide RNAs (gRNAs) that cleave conserved viral sequences across the virus phylogeny and developed an AAV-CRISPR-Cas13 therapeutics using in vitro viral plaque assay and in vivo EV-A71 lethally-infected mouse model.
FINDINGS
RESULTS
We show that treatment with a pool of AAV-CRISPR-Cas13-gRNAs designed using the bioinformatics pipeline effectively blocks viral replication and reduces viral titers in cells by >99.99%. We further demonstrate that AAV-CRISPR-Cas13-gRNAs prophylactically and therapeutically inhibited viral replication in infected mouse tissues and prevented death in a lethally challenged EV-A71-infected mouse model.
INTERPRETATION
CONCLUSIONS
Our results show that the bioinformatics pipeline designs efficient CRISPR-Cas13 gRNAs for direct viral RNA targeting to reduce viral loads. Additionally, this new antiviral AAV-CRISPR-Cas13 modality represents an effective direct-acting prophylactic and therapeutic agent against lethal RNA viral infections.
FUNDING
BACKGROUND
Agency for Science, Technology and Research (A∗STAR) Assured Research Budget, A∗STAR Central Research Fund UIBR SC18/21-1089UI, A∗STAR Industrial Alignment Fund Pre-Positioning (IAF-PP) grant H17/01/a0/012, MOE Tier 2 2017 (MOE2017-T2-1-078; MOE-T2EP30221-0005), and NUHSRO/2020/050/RO5+5/NUHS-COVID/4.
Identifiants
pubmed: 37390772
pii: S2352-3964(23)00247-5
doi: 10.1016/j.ebiom.2023.104682
pmc: PMC10363442
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104682Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests CTK, RCHL, TY, JJHC, and WLC have filed patents and provisional applications based on this work.
Références
N Engl J Med. 2015 May 14;372(20):1887-97
pubmed: 25938638
Front Microbiol. 2018 Oct 08;9:2422
pubmed: 30349526
FEMS Immunol Med Microbiol. 2007 Apr;49(3):324-9
pubmed: 17378896
Sci Adv. 2022 Jan 21;8(3):eabk2485
pubmed: 35044815
Antiviral Res. 2016 Oct;134:207-215
pubmed: 27623347
Nat Methods. 2016 Oct;13(10):868-74
pubmed: 27595405
J Biol Chem. 2018 Jul 27;293(30):11654-11658
pubmed: 29941452
Science. 2018 Oct 5;362(6410):86-91
pubmed: 30166439
Clin Exp Vaccine Res. 2017 Jan;6(1):4-14
pubmed: 28168168
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
Commun Biol. 2021 Mar 25;4(1):396
pubmed: 33767386
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cell. 2020 May 14;181(4):865-876.e12
pubmed: 32353252
Nat Rev Genet. 2020 Apr;21(4):255-272
pubmed: 32042148
Trends Microbiol. 2015 Jan;23(1):55-63
pubmed: 25456015
Mol Cell. 2018 Apr 19;70(2):327-339.e5
pubmed: 29551514
N Engl J Med. 2014 Feb 27;370(9):818-28
pubmed: 24571754
Trends Ecol Evol. 2008 Apr;23(4):188-93
pubmed: 18295930
Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):1219-24
pubmed: 21983920
Nat Commun. 2018 Apr 11;9(1):1386
pubmed: 29643370
Biomed Pharmacother. 2021 Apr;136:111239
pubmed: 33454599
Lancet Infect Dis. 2021 Mar;21(3):308-309
pubmed: 33031751
Virology. 2005 Oct 10;341(1):72-9
pubmed: 16083932
Lancet Neurol. 2010 Nov;9(11):1097-105
pubmed: 20965438
PLoS Pathog. 2015 Mar 23;11(3):e1004733
pubmed: 25799064
Nature. 2017 Oct 12;550(7675):280-284
pubmed: 28976959
Mol Ther. 2007 Nov;15(11):1931-8
pubmed: 17712333
Sci Rep. 2018 Mar 6;8(1):4087
pubmed: 29511232
Sci Rep. 2020 May 18;10(1):8159
pubmed: 32424333
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Hum Gene Ther Clin Dev. 2013 Jun;24(2):55-64
pubmed: 23808604
Sci Data. 2018 Feb 20;5:180017
pubmed: 29461515
Semin Cell Dev Biol. 2019 Dec;96:53-64
pubmed: 30953741
Biochim Biophys Acta. 2011 Mar;1809(3):211-9
pubmed: 21220056
Lancet. 2017 Aug 26;390(10097):849-860
pubmed: 28712537
Mol Cell. 2019 Dec 5;76(5):826-837.e11
pubmed: 31607545
Nat Biomed Eng. 2019 Oct;3(10):806-816
pubmed: 31332341
J Biomed Sci. 2019 Sep 3;26(1):65
pubmed: 31481071
Mol Ther Nucleic Acids. 2020 Mar 6;19:1460-1469
pubmed: 32160714
BMC Immunol. 2019 Jan 22;20(1):6
pubmed: 30669993
Nat Biotechnol. 2020 Jun;38(6):722-727
pubmed: 32518401
Nat Biotechnol. 2021 Jun;39(6):717-726
pubmed: 33536629
Cell. 2018 Apr 19;173(3):665-676.e14
pubmed: 29551272
Nat Rev Microbiol. 2018 Jun;16(6):368-381
pubmed: 29626210
Lancet Reg Health West Pac. 2022 Jan 02;20:100370
pubmed: 35036978
Drug Discov Today. 2017 Jan;22(1):17-30
pubmed: 27575999